NASDAQ:CALACalithera Biosciences Stock Price, Forecast & News

$5.89

-0.22 (-3.60 %)

(As of 05/27/2020 04:00 PM ET)

Add

Compare

Today's Range

$5.81

Now: $5.89▼

$6.18

50-Day Range

$4.42

MA: $6.41▼

$7.85

52-Week Range

$2.45

Now: $5.89▼

$8.18

Volume52,722 shs

Average Volume845,008 shs

Market Capitalization$414.89 million

P/E RatioN/A

Dividend YieldN/A

Beta2.36

Calithera Biosciences, Inc., a clinical-stage bio-pharmaceutical company, focuses on the discovery and development of small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. Its lead product candidate is CB-839, an inhibitor of glutaminase, which is in Phase II clinical trial to treat solid tumors. The company also offers INCB001158, an oral inhibitor of arginase that is in Phase I/II clinical trial for the treatment of hematology and oncology. The company is also developing CB-280, an oral arginase inhibitor for the treatment of cystic fibrosis; and CB-708, an orally administered small molecule inhibitor of CD73. It has a license agreement with Mars, Inc. to develop and commercialize Symbioscience's portfolio of arginase inhibitors for use in human healthcare. The company also has clinical trial collaboration with Bristol-Myers Squibb Company to evaluate nivolumab in combination with CB-839. In addition, it has a collaboration and license agreement with Incyte Corporation for the research, development, and commercialization of INCB001158, a small molecule arginase inhibitor for the treatment of hematology and oncology. Calithera Biosciences, Inc. was founded in 2010 and is headquartered in South San Francisco, California.

Beat the Market (BTM) Rank^™

3.5 Analyst's Opinion

Consensus Rating
Calithera Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $8.50, Calithera Biosciences has a potential upside of 44.3% from its current price of $5.89.
Amount of Analyst Coverage
Calithera Biosciences has only been the subject of 4 research reports in the past 90 days.

2.8 Community Rank

Outperform Votes
Calithera Biosciences has received 324 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Calithera Biosciences has received 248 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Calithera Biosciences has received 56.64% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Calithera Biosciences and other stocks. Vote “Outperform” if you believe CALA will outperform the S&P 500 over the long term. Vote “Underperform” if you believe CALA will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Calithera Biosciences does not currently pay a dividend.
Dividend Growth
Calithera Biosciences does not have a long track record of dividend growth.

1.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Calithera Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $13,741,588.00 in company stock.
Percentage Held by Insiders
Only 17.20% of the stock of Calithera Biosciences is held by insiders.
Percentage Held by Institutions
71.34% of the stock of Calithera Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6 Earnings and Valuation

Earnings Growth
Earnings for Calithera Biosciences are expected to grow in the coming year, from ($1.36) to ($1.22) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Calithera Biosciences is -3.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Calithera Biosciences is -3.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Calithera Biosciences has a P/B Ratio of 3.25. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

1.59 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:CALA

Previous Symbol

CUSIPN/A

CIK1496671

Webwww.calithera.com

Phone650-870-1000

Debt

Debt-to-Equity Ratio0.05

Current Ratio8.75

Quick Ratio8.75

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$22.25 million

Price / Sales18.65

Cash FlowN/A

Price / Cash FlowN/A

Book Value$1.81 per share

Price / Book3.25

Profitability

EPS (Most Recent Fiscal Year)($1.90)

Net Income$-89,860,000.00

Net MarginsN/A

Return on Equity-68.38%

Return on Assets-57.43%

Miscellaneous

Employees90

Outstanding Shares70,440,000

Market Cap$414.89 million

Next Earnings Date8/13/2020 (Estimated)

OptionableOptionable

Receive CALA News and Ratings via Email

Sign-up to receive the latest news and ratings for CALA and its competitors with MarketBeat's FREE daily newsletter.

Calithera Biosciences (NASDAQ:CALA) Frequently Asked Questions

How has Calithera Biosciences' stock been impacted by COVID-19 (Coronavirus)?

Calithera Biosciences' stock was trading at $5.23 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, CALA shares have increased by 12.6% and is now trading at $5.89. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Calithera Biosciences?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Calithera Biosciences in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Calithera Biosciences.

When is Calithera Biosciences' next earnings date?

Calithera Biosciences is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Calithera Biosciences.

How were Calithera Biosciences' earnings last quarter?

Calithera Biosciences Inc (NASDAQ:CALA) issued its quarterly earnings data on Thursday, May, 7th. The biotechnology company reported ($0.38) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.36) by $0.02. View Calithera Biosciences' earnings history.

What price target have analysts set for CALA?

5 equities research analysts have issued 1 year price objectives for Calithera Biosciences' stock. Their forecasts range from $6.00 to $10.00. On average, they anticipate Calithera Biosciences' stock price to reach $8.50 in the next twelve months. This suggests a possible upside of 44.3% from the stock's current price. View analysts' price targets for Calithera Biosciences.

Has Calithera Biosciences been receiving favorable news coverage?

News coverage about CALA stock has trended somewhat positive recently, InfoTrie Sentiment reports. InfoTrie identifies negative and positive news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Calithera Biosciences earned a media sentiment score of 1.6 on InfoTrie's scale. They also gave news coverage about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near future. View the latest news aboutCalithera Biosciences.

Who are some of Calithera Biosciences' key competitors?

Some companies that are related to Calithera Biosciences include Theravance Biopharma (TBPH), Arvinas (ARVN), Dicerna Pharmaceuticals (DRNA), Heron Therapeutics (HRTX), Zogenix (ZGNX), Arcus Biosciences (RCUS), Zymeworks (ZYME), Ligand Pharmaceuticals (LGND), CytoDyn (CYDY), Constellation Pharmaceuticals (CNST), Akebia Therapeutics (AKBA), Amneal Pharmaceuticals (AMRX), BELLUS Health (BLUSF), Opko Health (OPK) and Y-mAbs Therapeutics (YMAB). View all competitors.

What other stocks do shareholders of Calithera Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Calithera Biosciences investors own include Puma Biotechnology (PBYI), Incyte (INCY), Medivation (MDVN), BioMarin Pharmaceutical (BMRN), Celadon Group (CGI), Dynavax Technologies (DVAX), First Solar (FSLR), Camtek (CAMT), Plug Power (PLUG) and United Continental (UAL).

Who are Calithera Biosciences' key executives?

Calithera Biosciences' management team includes the following people:

Dr. Susan M. Molineaux, Co-Founder, CEO, Pres & Director (Age 66, Pay $887.04k)
Mr. Curtis C. Hecht, Chief Bus. Officer (Age 49, Pay $538.17k)
Dr. Keith Orford, Chief Medical Officer (Age 48, Pay $793.85k)
Ms. Stephanie Wong, Sr. VP of Fin. & Sec. (Age 46)
Ms. Jennifer McNealey, VP of Investor Relations & Strategy

What is Calithera Biosciences' stock symbol?

Calithera Biosciences trades on the NASDAQ under the ticker symbol "CALA."

Who are Calithera Biosciences' major shareholders?

Calithera Biosciences' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Primecap Management Co. CA (13.42%), BlackRock Inc. (6.34%), State Street Corp (1.42%), Sofinnova Investments Inc. (1.16%), Geode Capital Management LLC (1.15%) and Wellington Management Group LLP (0.79%). Company insiders that own Calithera Biosciences stock include Bvf Partners L P/Il, Keith Orford, Stephanie Wong, Susan Molineaux and Value Fund L P Biotechnology. View institutional ownership trends for Calithera Biosciences.

Which institutional investors are selling Calithera Biosciences stock?

CALA stock was sold by a variety of institutional investors in the last quarter, including Sofinnova Investments Inc., Squarepoint Ops LLC, Morgan Stanley, Two Sigma Investments LP, Primecap Management Co. CA, UBS Group AG, Wellington Management Group LLP, and Connor Clark & Lunn Investment Management Ltd.. Company insiders that have sold Calithera Biosciences company stock in the last year include Bvf Partners L P/Il, Keith Orford, and Stephanie Wong. View insider buying and selling activity for Calithera Biosciences.

Which institutional investors are buying Calithera Biosciences stock?

CALA stock was purchased by a variety of institutional investors in the last quarter, including Nuveen Asset Management LLC, State Street Corp, Geode Capital Management LLC, Russell Investments Group Ltd., AQR Capital Management LLC, Two Sigma Advisers LP, Los Angeles Capital Management & Equity Research Inc., and Bank of New York Mellon Corp. Company insiders that have bought Calithera Biosciences stock in the last two years include Bvf Partners L P/Il, Susan Molineaux, and Value Fund L P Biotechnology. View insider buying and selling activity for Calithera Biosciences.

How do I buy shares of Calithera Biosciences?

Shares of CALA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Calithera Biosciences' stock price today?

One share of CALA stock can currently be purchased for approximately $5.89.

How big of a company is Calithera Biosciences?

Calithera Biosciences has a market capitalization of $414.89 million and generates $22.25 million in revenue each year. The biotechnology company earns $-89,860,000.00 in net income (profit) each year or ($1.90) on an earnings per share basis. Calithera Biosciences employs 90 workers across the globe.

What is Calithera Biosciences' official website?

The official website for Calithera Biosciences is www.calithera.com.

How can I contact Calithera Biosciences?

Calithera Biosciences' mailing address is 343 OYSTER POINT BLVD. SUITE 200, SOUTH SAN FRANCISCO CA, 94080. The biotechnology company can be reached via phone at 650-870-1000 or via email at [email protected]

This page was last updated on 5/27/2020 by MarketBeat.com Staff